Citius Oncology, Inc.
NASDAQ:CTORDrug Manufacturers - General
+$0.03 today
- Market cap
- $51.83M
- Beta
- 3.42
- P/E (TTM)
- -1.6
- EPS (TTM)
- -$0.42
Volume 0.15M
Average 0.12M
CTOR Other Non-current Liabilities
Long-term obligations not reported separately, such as lease or pension liabilities.
Citius Oncology, Inc.NASDAQ: CTOR
Other Non-current Liabilities · Q2 FY2026 · quarter ended Mar 2026
Other non-current liabilities remains negative
Q2 FY2026 other non-current liabilities was $0, compared with $2.26M a year earlier. Over 3 fiscal years it compounded at +69.1% a year.
Context
- Other non-current liabilities amounted to 0.0% of total assets at the end of Q2 FY2026, down 2.5 pp from a year earlier.
- Other non-current liabilities increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether other non-current liabilities keeps falling in the next quarterly balance sheet after a -100.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Non-current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 2.78M USD
- Year-over-year change
- +61.2%
- 3-year CAGR
- +69.1%
| Period | Period end | Other Non-current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-09-30 | 2.78M | +61.2% |
| FY2024 | 2024-09-30 | 1.73M | +50.0% |
| FY2023 | 2023-09-30 | 1.15M | +100.0% |
| FY2022 | 2022-09-30 | 576K | — |
Other Non-current Liabilities vs competitors
How CTOR compares with its peers on the latest reported figures
- CTOR's Mar 2026 other non-current liabilities of $0 is the 9th highest of the 10 companies compared; the peer median is $2.14M.
- Its year-over-year change of -100.0% is the 6th highest of 7, against a peer median of -60.6%.
- Other non-current liabilities amounts to 0.0% of total assets for CTOR, versus a peer median of 1.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $638.46M | — | — | 126.0% | |
| Mar 2026 | $27.66M | +166.2% | +122.7% | 9.4% | |
| Mar 2026 | $21.25M | -67.8% | +590.1% | 32.1% | |
| Mar 2026 | $2.48M | -53.5% | -14.7% | 0.9% | |
| Mar 2026 | $2.14M | +13.0% | +12.9% | 1.8% | |
| Mar 2026 | $1.48M | — | — | 2.2% | |
| Mar 2026 | $818K | -95.7% | +52.7% | 0.9% | |
| Mar 2026 | $91K | — | -1.8% | 0.2% | |
CTORCitius Oncology, Inc. | Mar 2026 | $0 | -100.0% | +69.1% | 0.0% |
ACTUActuate Therapeutics Inc | Mar 2026 | $0 | -100.0% | — | 0.0% |
| Peer median (excluding CTOR) | $2.14M | -60.6% | +32.8% | 1.8% | |
Competitors are the stored peer set for CTOR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Citius Oncology, Inc.
NASDAQ:CTOR
Intrinsic Alpha fair value
Locked
Current Price
$0.56
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.